Severity of Fontan-Associated Liver Disease Correlates with Fontan Hemodynamics

被引:0
|
作者
Anastasia Schleiger
Madeleine Salzmann
Peter Kramer
Friederike Danne
Stephan Schubert
Christian Bassir
Tobias Müller
Hans-Peter Müller
Felix Berger
Stanislav Ovroutski
机构
[1] German Heart Center Berlin,Department of Congenital Heart Disease/Pediatric Cardiology
[2] Charité-Universitätsmedizin Berlin,Department of Pediatric Radiology
[3] Charité Universitätsmedizin Berlin,Department of Gastroenterology and Hepatology
[4] DZHK (German Center for Cardiovascular Research),Division of Cardiology, Department of Pediatrics
[5] Charité Universitätsmedizin Berlin,undefined
来源
Pediatric Cardiology | 2020年 / 41卷
关键词
Fontan-associated liver disease; Liver cirrhosis; Fontan surveillance; Fontan hemodynamics; Risk factors for FALD;
D O I
暂无
中图分类号
学科分类号
摘要
Fontan-palliated patients are at risk for the development of Fontan-associated liver disease (FALD). In this study, we performed a detailed hemodynamic and hepatic assessment to analyze the incidence and spectrum of FALD and its association with patients' hemodynamics. From 2017 to 2019, 145 patients underwent a detailed, age-adjusted hepatic examination including laboratory analysis (FibroTest®, n = 101), liver ultrasound (n = 117) and transient elastography (FibroScan®, n = 61). The median patient age was 16.0 years [IQR 14.2], and the median duration of the Fontan circulation was 10.3 years [IQR 14.7]. Hemodynamic assessment was performed using echocardiography, cardiopulmonary exercise capacity testing and cardiac catheterization. Liver ultrasound revealed hepatic parenchymal changes in 83 patients (70.9%). Severe liver cirrhosis was detectable in 20 patients (17.1%). Median liver stiffness measured by FibroScan® was 27.7 kPa [IQR 14.5], and the median Fibrotest® score was 0.5 [IQR 0.3], corresponding to fibrosis stage ≥ 2. Liver stiffness values and Fibrotest® scores correlated significantly with Fontan duration (P1 = 0.013, P2 = 0.012). Exercise performance was significantly impaired in patients with severe liver cirrhosis (P = 0.003). Pulmonary artery pressure and end-diastolic pressure were highly elevated in cirrhotic patients (P1 = 0.008, P2 = 0.003). Multivariable risk factor analysis revealed Fontan duration to be a major risk factor for the development of FALD (P < 0.001, OR 0.77, CI 0.68–0.87). In the majority of patients, hepatic abnormalities suggestive of FALD were detectable by liver ultrasound, transient elastography and laboratory analysis. The severity of FALD correlated significantly with Fontan duration and impaired Fontan hemodynamics. A detailed hepatic assessment is indispensable for long-term surveillance of Fontan patients.
引用
收藏
页码:736 / 746
页数:10
相关论文
共 50 条
  • [21] FONTAN-ASSOCIATED LIVER DISEASE: IS INSULIN SENSITIVITY IMPORTANT?
    Dodeja, Anudeep
    Urbina, Francesca
    Moore-Padilla, Michelle
    Mah, May Ling
    Bradley, David
    Bradley, Elisa
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 549 - 549
  • [22] Portal vein thrombosis in Fontan-associated liver disease
    Kaulitz, Renate
    Sieverding, Ludger
    Hofbeck, Michael
    CARDIOLOGY IN THE YOUNG, 2020, 30 (06) : 883 - 885
  • [23] Novel immunologic mechanisms for Fontan-associated liver disease
    Angelotti, Austin
    Dhesi, Maninder
    Bansal, Shyam S.
    Bradley, Elisa A.
    INTERNATIONAL JOURNAL OF CARDIOLOGY CONGENITAL HEART DISEASE, 2025, 19
  • [24] Fontan-associated liver disease: Implications for heart transplantation
    Greenway, Steven C.
    Crossland, David S.
    Hudson, Mark
    Martin, Steven R.
    Myers, Robert P.
    Prieur, Tim
    Hasan, Asif
    Kirk, Richard
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2016, 35 (01): : 26 - 33
  • [25] Fontan-associated liver disease: Spectrum of US findings
    Bae, Jung Min
    Jeon, Tae Yeon
    Kim, Jung Sun
    Kim, Seokhwi
    Hwang, Sook Min
    Yoo, Young
    Kim, Ji Hye
    EUROPEAN JOURNAL OF RADIOLOGY, 2016, 85 (04) : 850 - 856
  • [26] Predicting and maybe preventing Fontan-associated liver disease
    Rathod, Rahul H.
    HEART, 2023, 109 (04) : 248 - 249
  • [27] Literature review for Fontan-associated liver disease: An update
    Hsiao, Chung-Chen
    Ho, Cheng-Maw
    FORMOSAN JOURNAL OF SURGERY, 2023, 56 (02) : 68 - 68
  • [28] Fontan-associated liver disease and hepatocellular carcinoma in adults
    Kogiso, Tomomi
    Tokushige, Katsutoshi
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [29] Fontan-Associated Liver Disease: Evidence for Early Surveillance of Liver Health in Pediatric Fontan Patients
    Rathgeber, Steven L.
    Harris, Kevin C.
    CANADIAN JOURNAL OF CARDIOLOGY, 2019, 35 (02) : 217 - 220
  • [30] Fontan-associated liver disease after heart transplant
    Griffiths, Eric R.
    Lambert, Linda M.
    Ou, Zhining
    Shaaban, Akraam
    Rezvani, Maryam
    Carlo, Waldemar F.
    Schumacher, Kurt R.
    DiPaola, Frank
    O'Connor, Matthew J.
    Nandi, Deipanjan
    Zangwill, Steven
    McCulloch, Michael A.
    Friedland-Little, Joshua M.
    West, Shawn C.
    Lee, Teresa M.
    Alejos, Juan C.
    Chen, Sharon
    Molina, Kimberly M.
    PEDIATRIC TRANSPLANTATION, 2023, 27 (02)